Latest Tax Incentives News

Talius Group maintained steady revenue in Q2 2026, boosted by $2 million in new aged care contracts and a 10% increase in active subscriptions.

Clean TeQ Water has marked a milestone with its inaugural recurring revenue from ATA® technology and a 45% jump in quarterly customer receipts, underpinned by contract wins and project progress across global water and critical minerals markets.

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.

Yojee has transitioned its MOSAIC freight forwarding platform into commercial operations, securing multiple contracts including two long-term Everest Founding Partners and outlining a strategic AI-driven roadmap.

Energy Action Limited's unaudited FY26 results show a sharp profit decline to $0.45 million on stable revenue of $12.2 million, weighed down by lower R&D incentives and higher costs.

Argenica Therapeutics is gearing up for a pivotal late-stage clinical trial of its neuroprotective drug ARG-007 (xaranetide) in acute ischaemic stroke, backed by strong safety assays and solid funding.

Spenda Limited anticipates a significant R&D tax offset exceeding AUD 1.75 million for FY26, providing a timely cash boost amid its push towards cash-flow neutrality.

PainChek has received a $1.123 million R&D tax incentive refund for FY2025, reinforcing its cash reserves and underpinning ongoing development of AI pain assessment algorithms and US market validation.

Paradigm Biopharmaceuticals has strengthened its balance sheet with a combined $5.75 million cash inflow from Australian Government R&D tax incentives, supporting its pivotal Phase 3 osteoarthritis trial and regulatory efforts.

CONNEQT Health's June quarter saw record consumer revenue growth and a 70% jump in enterprise subscription ARR, supported by a $5.5 million placement and progress on its FDA regulatory pathway for its cloud-based vascular analytics platform.

Biotron has received pivotal regulatory feedback from the European Medicines Agency ruling out a Hybrid Marketing Authorisation for SedRx, prompting plans for pivotal clinical trials. The company also advances its lead antiviral candidate BIT-HBV001 against Hepatitis Delta Virus and appoints a new chairman.

AdNeo Limited achieved a record positive operating cash flow of $451k in Q4 FY26 and secured significant customer contracts, setting the stage for disciplined growth in FY27.